The prognostic and predictive value of serum CA19.9 in pancreatic cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Current staging methods for pancreatic cancer (PC) are inadequate, and biomarkers to aid clinical decision making are lacking. Despite the availability of the serum marker carbohydrate antigen 19.9 (CA19.9) for over two decades, its precise role in the management of PC is yet to be defined, and as a consequence, it is not widely used. METHODS: We assessed the relationship between perioperative serum CA19.9 levels, survival and adjuvant chemotherapeutic responsiveness in a cohort of 260 patients who underwent operative resection for PC. RESULTS: By specifically assessing the subgroup of patients with detectable CA19.9, we identified potential utility at key clinical decision points. Low postoperative CA19.9 at 3 months (median survival 25.6 vs 14.8 months, P=0.0052) and before adjuvant chemotherapy were independent prognostic factors. Patients with postoperative CA 19.9 levels>90 U/ml did not benefit from adjuvant chemotherapy (P=0.7194) compared with those with a CA19.9 of ≤90 U/ml (median 26.0 vs 16.7 months, P=0.0108). Normalization of CA19.9 within 6 months of resection was also an independent favorable prognostic factor (median 29.9 vs 14.8 months, P=0.0004) and normal perioperative CA19.9 levels identified a good prognostic group, which was associated with a 5-year survival of 42%. CONCLUSIONS: Perioperative serum CA19.9 measurements are informative in patients with detectable CA19.9 (defined by serum levels of >5 U/ml) and have potential clinical utility in predicting outcome and response to adjuvant chemotherapy. Future clinical trials should prioritize incorporation of CA19.9 measurement at key decision points to prospectively validate these findings and facilitate implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Goonetilleke, K. S., & Siriwardena, A. K. (2007) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2006.10.004 · Cited by 877
Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., et al. (2008) · JAMA · doi:10.1001/jama.299.9.1019 · Cited by 755
Specific Antigen in Serum of Patients with Colon Carcinoma
Koprowski, H., Herlyn, M., Steplewski, Z., & Sears, H. F. (1981) · Science · doi:10.1126/science.6163212 · Cited by 591
Ferrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Castillo, C. F.-D., & Warshaw, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3934 · Cited by 554
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400
Berger, A. C., Garcia, M., Hoffman, J. P., Regine, W. F., Abrams, R. A., Safran, H., Konski, A., Benson, A. B., MacDonald, J., & Willett, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6288 · Cited by 371
Margin Clearance and Outcome in Resected Pancreatic Cancer
Chang, D. K., Johns, A. L., Merrett, N. D., Gill, A. J., Colvin, E. K., Scarlett, C. J., Nguyen, N. Q., Leong, R. W. L., Cosman, P. H., Kelly, M. I., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5104 · Cited by 309
Self-citationButturini, G. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.17 · Cited by 309
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294
Hess, V., Glimelius, B., Grawe, P., Dietrich, D., Bodoky, G., Ruhstaller, T., Bajetta, E., Saletti, P., Figer, A., Scheithauer, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70001-9 · Cited by 239
ABH and Lewis histo‐blood group antigens in cancer
LE PENDU, J., MARIONNEAU, S., CAILLEAU‐THOMAS, A., ROCHER, J., LE MOULLAC‐VAIDYE, B., & CLÉMENT, M. (2001) · APMIS · doi:10.1111/j.1600-0463.2001.tb00011.x · Cited by 226
Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer
Schlieman, M. G. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.9.951 · Cited by 172
Boeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., & Heinemann, V. (2006) · Oncology · doi:10.1159/000094888 · Cited by 172
Kondo, N., Murakami, Y., Uemura, K., Hayashidani, Y., Sudo, T., Hashimoto, Y., Nakashima, A., Sakabe, R., Shigemoto, N., Kato, Y., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1033-0 · Cited by 169
Vestergaard, E. M., Hein, H. O., Meyer, H., Grunnet, N., Jørgensen, J. B., Wolf, H., & Orntoft, T. F. (1999) · PubMed · Cited by 164
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
Maisey, N. R., Norman, A. R., Hill, A., Massey, A., Oates, J., & Cunningham, D. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602760 · Cited by 162
Montgomery, R. C., Hoffman, J. P., Riley, L. B., Rogatko, A., Ridge, J. A., & Eisenberg, B. L. (1997) · Annals of Surgical Oncology · doi:10.1007/bf02305535 · Cited by 128
Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E., Zerbi, A., Di Carlo, V., & Villa, E. (2009) · Cancer · doi:10.1002/cncr.24302 · Cited by 125
Ørntoft, T. F., Vestergaard, E. M., Holmes, E., Jakobsen, J. S., Grunnet, N., Mortensen, M., Johnson, P., Bross, P., Gregersen, N., Skorstengaard, K., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32260 · Cited by 125
The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer
Kang, C. M., Kim, J. Y., Choi, G. H., Kim, K. S., Choi, J. S., Lee, W. J., & Kim, B. R. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2006.10.007 · Cited by 111
Biankin, A. V., Kench, J. G., Colvin, E. K., Segara, D., Scarlett, C. J., Nguyen, N. Q., Chang, D. K.-F., Morey, A. L., Lee, C. S., Pinese, M., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.009 · Cited by 98
Self-citationKim, Y. C., Kim, H. J., Park, J. H., Park, D. I., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., & Shin, J. H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05935.x · Cited by 94
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Barton, J. G., Bois, J. P., Sarr, M. G., Wood, C. M., Qin, R., Thomsen, K. M., Kendrick, M. L., & Farnell, M. B. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0849-z · Cited by 93
Ong, S. L., Sachdeva, A., Garcea, G., Gravante, G. G., Metcalfe, M. S., Lloyd, D., Berry, D. P., & Dennison, A. R. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0289-8 · Cited by 93
Wong, D., Ko, A. H., Hwang, J., Venook, A. P., Bergsland, E. K., & Tempero, M. A. (2008) · Pancreas · doi:10.1097/mpa.0b013e31816d8185 · Cited by 89
Hernandez, J. M., Cowgill, S. M., Al-Saadi, S., Collins, A., Ross, S. B., Cooper, J., Villadolid, D., Zervos, E. E., & Rosemurgy, A. S. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0696-3 · Cited by 54
Clinical usefulness of CA-19-9 in pancreatic carcinoma
Nakao, A., Oshima, K., Nomoto, S., Takeda, S., Kaneko, T., Ichihara, T., Kurokawa, T., Nonami, T., & Takagi, H. (1998) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199807/08)15:1<15::aid-ssu4>3.0.co;2-z · Cited by 38
Cited by
Molecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892
Self-citationRoles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313030003 · Cited by 398
Hartwig, W., Strobel, O., Hinz, U., Fritz, S., Hackert, T., Roth, C., Büchler, M. W., & Werner, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2809-1 · Cited by 301
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Lee, T., Teng, T. Z. J., & Shelat, V. G. (2020) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v12.i12.468 · Cited by 293
Metadata
- Authors
- Humphris, J. L., Chang, D. K., Johns, A. L., Scarlett, C. J., Pajic, M., Jones, M. D., Colvin, E. K., Nagrial, A., Chin, V. T., Chantrill, L. A., Samra, J. S., Gill, A. J., Kench, J. G., Merrett, N. D., Das, A., Musgrove, E. A., Sutherland, R. L., & Biankin, A. V.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 23
- Issue
- 7
- Pages
- 1713-1722
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2136339108
- Cited by
- 312
- References
- 33
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.